60 likes | 89 Views
Several researches and clinical trials have shown that Peptide Receptor Radionuclide Therapy (PRRT) is an exciting and effective advancement in the treatment of Neuroendocrine Tumors (NETs).<br>
E N D
Several researches and clinical trials have shown that Peptide Receptor Radionuclide Therapy (PRRT) is an exciting and effective advancement in the treatment of Neuroendocrine Tumors (NETs).
Peptide Receptor Radionuclide Therapy (PRRT) is a recommended treatment option for patients with metastatic inoperable neuroendocrine tumor(s) which are positive on Somatostatin Receptor Imaging (Ga68-DOTATATE PET CT). It is also recommended for NET patients who cannot undergo surgery and for patients who are not responding to other therapies.
The objective of Peptide Receptor Radionuclide Therapy (PRRT) is to provide symptom relief, slow down or stop tumor progression, to increase survival and improve quality of life.
Peptide receptor radionuclide therapy (PRRT) is fast proving to be paradigm shifting approach to the treatment of neuroendocrine tumors.
For more information on PRRT, do call us at +91 98111 27080, or write to us at info@nuclearmedicinetherapy.in or visit https://nuclearmedicinetherapy.in/
For more information on PRRT, do call us at +91 98111 27080, or write to Dr. Ishita B. Sen at dr.ishitasen@nuclearmedicinetherapy.inor consult us at https://nuclearmedicinetherapy.in/consult-us